What Is MLR Review? Medical, Legal and Regulatory Review Explained

Every promotional claim a pharmaceutical company makes in an email, sales aid, banner, or slide has to survive MLR review before it ever reaches a physician. It is the single biggest bottleneck between a good idea and an approved asset, and for most teams it is the part of the job nobody enjoys.

This page explains what MLR review actually means, what the three letters stand for, how the gate works, and how the terminology differs across regions. For the stage-by-stage walkthrough, see the MLR review process.

What is MLR review?

MLR review is the process by which a pharmaceutical company's Medical, Legal, and Regulatory teams review and approve promotional and scientific content before it is published. Its purpose is to confirm that every claim is accurate, fairly balanced, and fully substantiated by an approved source, so the company stays compliant with regulations like the FDA's rules on prescription drug promotion and the equivalent codes in other markets.

In practice, MLR review is a sign-off gate. A piece of content, usually called a "job" or an "asset," is submitted for review, each reviewer adds comments, the creator revises, and the cycle repeats until every reviewer signs off. Only then can the asset go live.

It sounds simple. It almost never is.

What does MLR stand for?

MLR stands for Medical, Legal, and Regulatory, the three functions that have to approve promotional material:

• Medical confirms that every claim is scientifically accurate and properly supported by the evidence.
• Legal checks for liability, intellectual property, and contractual risk.
• Regulatory confirms the piece complies with the relevant promotional rules and the product's approved label (the prescribing information).

You will also hear the process itself called promotional review or copy review. The cross-functional team that carries it out is usually called the Promotional Review Committee (PRC), so PRC names the committee, not the process, even though the two get used interchangeably in everyday conversation.

One important note for global teams: MLR and PRC are essentially US terms. As experienced reviewers like to point out, the UK and European codes don't talk about "review" at all; they refer to medical approval, with a single named signatory who is personally accountable for the final piece. The underlying work is similar everywhere, but the vocabulary, and the accountability model behind it, are not. If you operate across regions, don't assume the US workflow maps cleanly onto the ABPI or EFPIA world.

Who is responsible for MLR review?

All three functions are, and no single model dominates the industry. Medical confirms scientific accuracy, legal confirms liability and IP exposure, and regulatory confirms compliance with the approved label. No piece advances until all three sign off.

Accountability is a separate question from who does the work, and practitioners answer it differently: in a 2024 audience poll run by Impatient Health, 52% said primary accountability for compliance should sit with a cross-functional team, well ahead of a dedicated compliance officer (19%) or senior medical leadership alone (11%). MLR is a team sport. We break the full ownership and accountability data down in who owns MLR review.

How MLR review works as a gate

MLR review is a sign-off gate, not a single meeting. Content is submitted, each of the three functions reviews it independently, the creator revises against their comments, and the piece loops until every function signs off. Only then is it approved, dated, and released.

Almost every company runs the same five stages: create and submit, review, revise and resubmit, approve and date, distribute. The third stage is where the calendar actually goes, because it can repeat many times. We walk through all five, and what happens inside each, in the MLR review process, step by step.

Why MLR review takes so long

Industry benchmarks put the average content approval cycle at around 21 days, and that is just the average. Reviewers routinely describe promotional pieces that come back ten or more times, carrying thousands of accumulated comments, before they finally clear. We unpack the economics of that in the $30 billion content-waste problem.

The time burden on reviewers is real and measurable. In a 2024 promotional-review benchmark from Canopy, roughly two out of three reviewers spend at least 15% of their working week on promotional review, and about one in three spend 25% or more, which can mean ten to fifteen or more hours a week, frequently spilling into evenings and weekends. Medical directors carry their own share: in a separate Impatient Health poll, 38% estimated they spend between 10% and 20% of their total time on MLR, and another 27% put it between 21% and 30%.

The causes are rarely medical complexity. They are submissions that arrive without claims linked and anchored to their sources, reference errors and claim drift, the marketing-versus-medical tug-of-war over how ambitious a claim can be, and the absence of any capacity buffer when volume spikes. We take each of those apart in why promotional materials get sent back 10+ times, and cover the capacity problem specifically in scaling MLR review.

Add it up and a pattern emerges: MLR is slow not because review is hard, but because what arrives for review usually isn't ready to be reviewed.

MLR review and AI: where it helps, and where it hurts

It is tempting to throw a general-purpose AI assistant at the problem. Don't, at least not a generic one.

Tools like ChatGPT or Microsoft Copilot are not regulatory-ready. They treat facts as suggestions, they are not anchored to your approved label or your reference library, and they will confidently invent a citation that does not exist. In an MLR context, a single hallucinated or misattributed reference slipping into a submission is exactly the kind of error the whole process exists to catch.

Practitioners see this clearly. In the Impatient Health polls, asked where AI offers the most genuine near-term value in MLR, the top answers were speeding up initial data gathering and fact-checking (27%) and identifying inconsistencies or missing information in materials (27%), both of them narrow, assistive tasks. Tellingly, asked in a related poll which AI claim is most overstated, the top answer (again 27%) was "speeding up compliance and regulatory processes." The people doing the work are optimistic about AI as an assistant and skeptical of it as a replacement.

That instinct is right, and it shows up in how they think about accountability. Asked who is responsible if an AI-assisted piece causes a compliance breach, 39% of those polled pointed to the human who performed the final review, more than blamed the team, the department head, or the AI vendor. The lesson is consistent: keep a human in the driver's seat, even in an increasingly automated car. AI should make the reviewer faster and the submission cleaner; it should never make the decision.

How to speed up MLR review

The fix is not to hire more agencies to produce more drafts. It is to make sure that what reaches review is already in good shape. The principle is to shift compliance left, into the drafting phase, instead of discovering every problem at the review meeting. That target state has a name, MLR review readiness, and a checklist you can test a submission against. In practice that means building and maintaining a core-claims library, linking and anchoring every claim to its exact source line during drafting rather than after, and formatting references cleanly so they do not generate review comments of their own. (If you need to turn a PubMed record into a clean reference fast, our free AMA citation generator does it in one paste.)

The habits that make the first round count, and the rework they eliminate, are covered in full in the MLR review process.

This is exactly the gap PharmaText.ai was built to close. Our Precision Traceability engine anchors every claim to specific coordinates in your uploaded PDFs as the content is drafted, so the package that reaches MLR is already linked, already anchored, and ready to be verified rather than fixed. The goal is simple: turn first-round approval from a lucky outcome into the normal one. You can read about why this work belongs upstream of Veeva.

MLR review FAQ

What does MLR stand for? Medical, Legal, and Regulatory, the three functions that review and approve pharmaceutical promotional content before publication.

What is MLR in pharma? In pharma, MLR is the mandatory internal review that confirms a promotional or scientific asset is accurate, balanced, compliant with the product's approved label, and substantiated by approved references before it can be used.

What is the difference between MLR and PRC? They are not quite the same thing. MLR, also called promotional or copy review, is the review process itself. The PRC, or Promotional Review Committee, is the cross-functional team that performs it. Both terms are US-centric; UK and European codes instead refer to medical approval by a named signatory.

What does MLR mean in pharma? In pharma, MLR is shorthand for the Medical, Legal, and Regulatory review that promotional and scientific content must clear before it can be used. The same gate is also called promotional review or copy review.

How long does MLR review take? Industry benchmarks put the average approval cycle at roughly 21 days, but poorly prepared pieces can cycle back many times and take far longer. The biggest driver of speed is how review-ready the submission is on day one. See the MLR review process for the stage-by-stage breakdown.

Who signs off on MLR review? Medical, legal, and regulatory reviewers each sign off. In many companies the medical director is the primary medical reviewer, though accountability is increasingly held by a cross-functional team.

Related: walk through the MLR review process step by step, see why your MLR process is broken before review even starts, the $30 billion content-waste problem and the 21-day approval cycle, or format a clean primary-source citation with our free AMA citation generator.

Sources: data presented at 2024 industry webinars by Canopy and Impatient Health; the underlying reports are not publicly available.